Canada - English - Health Canada

apotex inc - tryptophan - tablet - 750mg - tryptophan 750mg - antidepressants

Canada - English - Health Canada

bausch health, canada inc. - tryptophan - capsule - 500mg - tryptophan 500mg - miscellaneous antidepressants

Canada - English - Health Canada

bausch health, canada inc. - tryptophan - tablet - 1g - tryptophan 1g - miscellaneous antidepressants

Canada - English - Health Canada

bausch health, canada inc. - tryptophan - tablet - 500mg - tryptophan 500mg - miscellaneous antidepressants

Canada - English - Health Canada

bausch health, canada inc. - tryptophan - tablet - 250mg - tryptophan 250mg - miscellaneous antidepressants

Canada - English - Health Canada

bausch health, canada inc. - tryptophan - tablet - 750mg - tryptophan 750mg - miscellaneous antidepressants

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

l-isoleucine 5.9mg, l-leucine 18.3, l-lysine 25mg, l-methionine 9.2mg, l-phenylalanine 5mg, l-threnine 4.2mg, l-tryptophan 5mg, l-valine cholecalciferol 200i.u, thiamine 5mg, calcium panthothenate 5mg, cyanocobalamin 2.5mg, folic acid 40mg, vitamin a 2500

United States - English - NLM (National Library of Medicine)

eon labs, inc. - oxaprozin (unii: mhj80w9lrb) (oxaprozin - unii:mhj80w9lrb) - oxaprozin 600 mg - oxaprozin tablets are indicated: oxaprozin is contraindicated in the following patients: risk summary use of nsaids, including oxaprozin, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of oxaprozin use between about 20 and 30 weeks of gestation, and avoid oxaprozin use at about 30 weeks of gestation and later in pregnancy (see clinical considerations, data). premature closure of fetal ductus arteriosus use of nsaids, including oxaprozin, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. oligohydramnios/neonatal renal impairment use of nsaids at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. data from observational studies regarding other potential em

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - celecoxib capsules are indicated for the management of the signs and symptoms of oa [ see clinical studies (14.1) ] for the management of the signs and symptoms of ra [ see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [ see clinical studies (14.3) ] for the management of the signs and symptoms of as [ see clinical studies (14.4) ] for the management of acute pain in adults [ see clinical studies (14.5) ] for the management of primary dysmenorrhea [ see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients : - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [ see warnings and precautions

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 50 mg